$GO

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Notable upgrades include Target (TGT) to Buy at HSBC with a $190 target, and Grocery Outlet (GO) to Buy at Bank of America with a $15 target. Downgrades include Ally Financial (ALLY) to Equal Weight at Wells Fargo with a $42 target, and Moderna (MRNA) to Sell at Citigroup with an $80 target.

Original reporting
Published Sep 30, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More — source image
Decision brief

The 30-second read

$GOBullishLow
01

Why it matters

The list provides fresh rating changes that can influence short-term price moves for the listed tickers.

02

Market read

While not a major market-moving event, the new ratings offer actionable signals for traders focusing on the affected stocks.

03

What to watch

Macro rate environment could dampen upside despite positive ratings.

Relevance 5/10Novelty 5/10Timing: pre-market today

Background

Daily roundup of analyst upgrades, downgrades, and initiations across multiple US-listed companies.

Company-level read

Ticker impact

$GOBullishMedium confidence
Context

Grocery Outlet Holding upgraded to Buy with target raised to $15.

Expected impact

likely upside as investors price in the higher target.

Evidence & confidence

Buy rating and higher target suggest improved fundamentals.

$NICEBullishMedium confidence
Context

Nice upgraded to Outperform with $150 target.

Expected impact

potential upward pressure from rating change.

Evidence & confidence

Higher target and upgrade indicate better earnings expectations.

$PNFPBullishMedium confidence
Context

Pinnacle Financial Partners upgraded to Overweight with $118 target.

Expected impact

likely modest upside.

Evidence & confidence

Analyst confidence reflected in higher price objective.

$TGTBullishMedium confidence
Context

Target upgraded to Buy with $190 target.

Expected impact

upward pressure expected.

Evidence & confidence

Higher target signals stronger sales outlook.

$ALLYBearishMedium confidence
Context

Ally Financial cut to Equal Weight, target lowered to $42.

Expected impact

potential downside pressure.

Evidence & confidence

Reduced target reflects weaker outlook.

$BKUBearishMedium confidence
Context

BankUnited downgraded to Equal Weight, target $47.

Expected impact

likely downside.

Evidence & confidence

Lower target indicates concerns.

$DOWBearishMedium confidence
Context

Dow downgraded to Neutral, target $30.

Expected impact

possible slight pressure.

Evidence & confidence

Target cut suggests weaker expectations.

$MBLYBearishMedium confidence
Context

Mobileye Global cut to Equal Weight, target $9.

Expected impact

downward pressure likely.

Evidence & confidence

Lower target reflects reduced growth view.

Market effects

Broad analyst rating changes may affect financial services and tech sectors.

US equity market sentiment could shift modestly.

Limited to US-listed equities; no direct global impact.

Counterpoint

Some upgrades may be premature given broader market weakness.

Key entities

  • Bank of America

    Upgraded Grocery Outlet Holding.

  • Wells Fargo

    Downgraded Ally Financial and BankUnited.

Related articles

$MRNAHigh

ESMO26: Moderna, MSD reveal cancer jab data early after leak

Moderna and MSD (Merck & Co) released early data for their melanoma vaccine, INTerpath-001, showing a 42% reduction in recurrence or death risk when combined with Keytruda. The study met expectations, with 82.2% recurrence-free survival at 24 months. Shares fell after a data leak but partially recovered. ESMO is investigating the breach. Analysts suggest potential billion-dollar sales if approved.

$MRNAHighAI 8/10

Moderna Sinks 17.6% Despite Melanoma Win

Moderna (MRNA) shares dropped 17.6% after early data leak from its melanoma vaccine trial with Merck. The vaccine, combined with Keytruda, reduced recurrence or death risk by 42%. Despite positive results, shares fell due to high expectations. UBS and BMO analysts noted strong data but acknowledged inflated expectations. Volume reached 49.9m shares.

$MRNAHigh

Moderna Sinks 18% on Leaked Melanoma Data: “Benefit Was Greater After Six Months”

Moderna's stock fell 17.6% to $202.63 after leaked Phase 3 data for its melanoma vaccine showed a 42% risk reduction, below investor expectations. The data showed a 58% risk reduction after six months. Moderna and Merck, which shares costs and profits, are awaiting full data presentation at ESMO. Analysts consider the data approvable but are reassessing commercial potential.